Lipid Disorder Treatment Market Size, Share, And Growth Report 2032

Lipid Disorder Treatment Market Size

The global Lipid Disorder Treatment market size was worth around USD 3.12 billion in 2023 and is predicted to grow to around USD 5.10 billion by 2032 with a compound annual growth rate (CAGR) of roughly 5.6% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Lipid Disorder Treatment market on a global and regional level.

Request Free Sample

Lipid Disorder Treatment Market: Overview

Lipid disorder includes a broad range of metabolic conditions that affect lipid levels in the blood. Lipid disorders are usually characterized by increased levels of cholesterol, lipoproteins and/or triglycerides in the blood which may relate to increased risk of cardiovascular disease. Most of these disorders are acquired through sedentary lifestyle, obesity, alcoholism, inactivity and lack of exercise. The risk due to congenital causes is less common. Blood lipid profile includes triglycerides, HDL, LDL and total cholesterol. Lipid disorder management and treatment involves use of lipid lowering agents (mainly use of statins) and lifestyle modifications.

The demand for lipid disorder treatment market is driven by increasing prevalence of LDL and triglyceride associated lipid disorders, growing prevalence of cardiovascular diseases, changing eating habits and sedentary lifestyle across the globe. Also, focus of major players on development of novel treatment options, increasing geriatric population and increasing health awareness are other factors that boost the market growth. Emerging markets with large population base and increasing geriatric population are expected to bring new growth opportunities for major market players operating in the global lipid disorder treatment.

The study includes drivers and restraints for the lipid disorder treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the lipid disorder treatment market on a global as well as regional level.

Request Free Sample

In order to give the users of this report a comprehensive view on the lipid disorder treatment market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the lipid disorder treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the lipid disorder treatment market on global and regional basis.

Lipid Disorder Treatment Market: Segmentation

The study provides a crucial view on the lipid disorder treatment by segmenting the market based on drug type, indication, distribution channel and region. All the segments of lipid disorder treatment market have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

Based on drug type, global lipid disorder treatment market is bifurcated into pravastatin, simvastatin, rosuvastatin, fluvastatin, atorvastatin and other drugs. Atorvastatin drug type segment accounted for largest market share in 2023 whereas rosuvastatin segment is expected to witness rapid CAGR over the forecast period. Effectiveness of atorvastatin against bad cholesterol has led to their increased use for treating cardiovascular disorders and reducing triglyceride levels and thus account for largest market share.

Based on indication market is segmented into heterozygous familial hypercholesterolemia, familial hypertriglyceridemia, familial dysbetalipoproteinemia, familial defective apolipoprotein b-100, familial combined hyperlipidemia and other indications.

The distribution channel segment is divided Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Retail pharmacies segment held largest market share due to high number of retail pharmacies across the globe. Online pharmacies will witness rapid growth over the forecast period.

Lipid Disorder Treatment Market: Report Scope

Lipid Disorder Treatment Market: Regional Analysis

North America dominated the global lipid disorder treatment market in 2023. Increasing prevalence of lipid disorders, increasing risk of related cardiovascular diseases, and growing awareness are factors driving the market in this region. Europe was second largest regional market. Presence of developed infrastructure, and increasing awareness and prevalence of lipid disorders are some of factors that boost market growth in this region. Latin America is expected to witness moderate growth over the forecast period. Asia Pacific region will exhibit highest growth for lipid disorder treatment market in the coming years. Increasing geriatric population base with high vulnerability to metabolic disorders, sedentary lifestyle, growing prevalence of lipid disorders are factors promoting lipid disorder treatment market growth in Asia Pacific. Middle East and Africa will see considerable growth in coming years.

Lipid Disorder Treatment Market: Competitive Players

Major players included in the report are:

• Mylan Pharmaceuticals
• Teva Pharmaceuticals
• Kowa Pharmaceuticals America Inc.
• Novartis AG
• Pfizer Inc.
• Astrazeneca Plc
• Sun Pharmaceuticals Industries Ltd.
• Glenmark Pharmaceuticals Ltd.
• Wockhardt Limited
• Emcure Pharmaceuticals Ltd.
• Merck & Co. 

The Global Lipid Disorder Treatment Market is segmented as follows:

Global Lipid Disorder Treatment Market: By Drug Type

• Atorvastatin
• Fluvastatin
• Rosuvastatin
• Simvastatin
• Pravastatin
• Other Drugs

Global Lipid Disorder Treatment Market: By Indication

• Heterozygous Familial Hypercholesterolemia
• Familial Hypertriglyceridemia
• Familial Dysbetalipoproteinemia
• Familial Defective Apolipoprotein B-100
• Familial Combined Hyperlipidemia
• Other Indications

Global Lipid Disorder Treatment Market: By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Lipid Disorder Treatment Market: By Region

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa